Navare Arti T, Mast Fred D, Olivier Jean Paul, Bertomeu Thierry, Neal Maxwell, Carpp Lindsay N, Kaushansky Alexis, Coulombe-Huntington Jasmin, Tyers Mike, Aitchison John D
Center for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, Washington, USA.
Institute for Research in Immunology and Cancer, Université de Montréal, Montreal, Quebec, Canada.
bioRxiv. 2020 Nov 6;221(11):2020.10.12.336487. doi: 10.1101/2020.10.12.336487.
Viruses co-opt host proteins to carry out their lifecycle. Repurposed host proteins may thus become functionally compromised; a situation analogous to a loss-of-function mutation. We term such host proteins viral-induced hypomorphs. Cells bearing cancer driver loss-of-function mutations have successfully been targeted with drugs perturbing proteins encoded by the synthetic lethal partners of cancer-specific mutations. Synthetic lethal interactions of viral-induced hypomorphs have the potential to be similarly targeted for the development of host-based antiviral therapeutics. Here, we use GBF1, which supports the infection of many RNA viruses, as a proof-of-concept. GBF1 becomes a hypomorph upon interaction with the poliovirus protein 3A. Screening for synthetic lethal partners of GBF1 revealed ARF1 as the top hit, disruption of which, selectively killed cells that synthesize poliovirus 3A. Thus, viral protein interactions can induce hypomorphs that render host cells vulnerable to perturbations that leave uninfected cells intact. Exploiting viral-induced vulnerabilities could lead to broad-spectrum antivirals for many viruses, including SARS-CoV-2.
Using a viral-induced hypomorph of GBF1, Navare et al., demonstrate that the principle of synthetic lethality is a mechanism to selectively kill virus-infected cells.
病毒会利用宿主蛋白来完成其生命周期。因此,被重新利用的宿主蛋白可能在功能上受到损害,这种情况类似于功能丧失突变。我们将这类宿主蛋白称为病毒诱导的亚效等位基因。携带癌症驱动功能丧失突变的细胞已成功地被靶向作用于癌症特异性突变的合成致死伙伴所编码蛋白质的药物所作用。病毒诱导的亚效等位基因的合成致死相互作用有可能被类似地靶向用于开发基于宿主的抗病毒疗法。在这里,我们以支持多种RNA病毒感染的GBF1为例进行概念验证。GBF1与脊髓灰质炎病毒蛋白3A相互作用后会成为亚效等位基因。对GBF1的合成致死伙伴进行筛选,结果显示ARF1是最显著的命中靶点,破坏该靶点会选择性地杀死合成脊髓灰质炎病毒3A的细胞。因此,病毒蛋白相互作用可诱导亚效等位基因,使宿主细胞易受能使未感染细胞保持完整的干扰因素影响。利用病毒诱导的脆弱性可能会产生针对包括SARS-CoV-2在内的多种病毒的广谱抗病毒药物。
纳瓦雷等人利用GBF1的病毒诱导亚效等位基因,证明了合成致死原理是一种选择性杀死病毒感染细胞的机制。